Is PTCT or PGEN more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% Precigen -646.99% 717.50% 58.48%

Does the media favor PTCT or PGEN?

In the previous week, PTC Therapeutics had 11 more articles in the media than Precigen. MarketBeat recorded 17 mentions for PTC Therapeutics and 6 mentions for Precigen. Precigen's average media sentiment score of 1.20 beat PTC Therapeutics' score of 0.40 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CNTA or PGEN?

In the previous week, Precigen had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 4 mentions for Centessa Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Centessa Pharmaceuticals' score of 0.73 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PGEN or MIRM?

In the previous week, Precigen had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 5 mentions for Mirum Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Mirum Pharmaceuticals' score of 0.98 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RYTM or PGEN?

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 6 articles in the media. Precigen's average media sentiment score of 1.20 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COGT or PGEN?

In the previous week, Precigen had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Precigen and 3 mentions for Cogent Biosciences. Precigen's average media sentiment score of 1.20 beat Cogent Biosciences' score of 0.74 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Precigen (PGEN) Competitors

$5.86 +0.34 (+6.16%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$5.82 -0.04 (-0.77%)

As of 06/26/2026 07:57 PM Eastern

Compare

PGEN vs. PTCT, CNTA, MIRM, RYTM, and COGT

Should you buy Precigen stock or one of its competitors? MarketBeat compares Precigen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precigen include PTC Therapeutics (PTCT), Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Precigen compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

PTC Therapeutics has higher revenue and earnings than Precigen. PTC Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	4.05	$682.64M	-$2.33	N/A
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A

PTC Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Precigen has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

PTC Therapeutics presently has a consensus target price of $91.36, suggesting a potential upside of 8.20%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 113.31%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

33.5% of Precigen shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PTC Therapeutics has a net margin of -22.58% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Precigen	-646.99%	717.50%	58.48%

In the previous week, PTC Therapeutics had 11 more articles in the media than Precigen. MarketBeat recorded 17 mentions for PTC Therapeutics and 6 mentions for Precigen. Precigen's average media sentiment score of 1.20 beat PTC Therapeutics' score of 0.40 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precigen beats PTC Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Precigen compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Centessa Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Precigen has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Precigen. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Precigen	-646.99%	717.50%	58.48%

In the previous week, Precigen had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 4 mentions for Centessa Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Centessa Pharmaceuticals' score of 0.73 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Centessa Pharmaceuticals currently has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 113.31%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Precigen beats Centessa Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Precigen compare to Mirum Pharmaceuticals?

Precigen (NASDAQ:PGEN) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Mirum Pharmaceuticals has higher revenue and earnings than Precigen. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A
Mirum Pharmaceuticals	$569.61M	13.23	-$23.36M	-$13.61	N/A

Mirum Pharmaceuticals has a net margin of -140.24% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Precigen has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

33.5% of Precigen shares are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Precigen had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 5 mentions for Mirum Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Mirum Pharmaceuticals' score of 0.98 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen currently has a consensus target price of $12.50, indicating a potential upside of 113.31%. Mirum Pharmaceuticals has a consensus target price of $139.80, indicating a potential upside of 13.12%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Precigen beats Mirum Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Precigen compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Rhythm Pharmaceuticals has higher revenue and earnings than Precigen. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A

Rhythm Pharmaceuticals presently has a consensus price target of $133.13, suggesting a potential upside of 21.20%. Precigen has a consensus price target of $12.50, suggesting a potential upside of 113.31%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Precigen	-646.99%	717.50%	58.48%

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 6 articles in the media. Precigen's average media sentiment score of 1.20 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Precigen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

33.5% of Precigen shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Precigen beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Precigen compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Precigen has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Precigen	-646.99%	717.50%	58.48%

In the previous week, Precigen had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Precigen and 3 mentions for Cogent Biosciences. Precigen's average media sentiment score of 1.20 beat Cogent Biosciences' score of 0.74 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.5% of Precigen shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Precigen has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A

Cogent Biosciences currently has a consensus target price of $43.73, suggesting a potential upside of 14.72%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 113.31%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Precigen beats Cogent Biosciences on 12 of the 16 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.97B	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.12%
P/E Ratio	-4.97	21.56	25.76	24.17
Price / Sales	215.82	335.68	556.00	99.02
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	97.67	8.34	10.77	6.35
Net Income	-$250.64M	$23.91M	$3.57B	$337.63M
7 Day Performance	21.58%	6.85%	3.17%	0.43%
1 Month Performance	33.18%	4.25%	1.86%	0.14%
1 Year Performance	312.68%	65.92%	34.39%	27.64%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	3.4996 of 5 stars	$5.86 +6.2%	$12.50 +113.3%	+309.8%	$1.97B	$9.68M	N/A	190	Positive News High Trading Volume
PTCT PTC Therapeutics	2.352 of 5 stars	$76.77 +2.2%	$91.36 +19.0%	+70.4%	$6.23B	$1.73B	N/A	1,410	Insider Trade High Trading Volume
CNTA Centessa Pharmaceuticals	2.0359 of 5 stars	$39.76 +0.1%	$41.33 +4.0%	N/A	$6.14B	$15M	N/A	200	Short Interest Decrease
MIRM Mirum Pharmaceuticals	2.2638 of 5 stars	$101.00 +1.7%	$139.80 +38.4%	+144.4%	$6.06B	$521.31M	N/A	140	Positive News Analyst Downgrade
RYTM Rhythm Pharmaceuticals	2.5083 of 5 stars	$89.70 +1.5%	$132.63 +47.9%	+78.8%	$6.06B	$189.76M	N/A	140	Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors

PGEN vs. PTCT, CNTA, MIRM, RYTM, and COGT

How does Precigen compare to PTC Therapeutics?

Summary

How does Precigen compare to Centessa Pharmaceuticals?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Summary

How does Precigen compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precigen (PGEN) Competitors

PGEN vs. PTCT, CNTA, MIRM, RYTM, and COGT

How does Precigen compare to PTC Therapeutics?

Which has higher earnings & valuation, PTCT or PGEN?

Which has more volatility & risk, PTCT or PGEN?

Do analysts rate PTCT or PGEN?

Do insiders and institutionals hold more shares of PTCT or PGEN?

Is PTCT or PGEN more profitable?

Does the media favor PTCT or PGEN?

Summary

How does Precigen compare to Centessa Pharmaceuticals?

Which has more risk and volatility, CNTA or PGEN?

Which has stronger earnings & valuation, CNTA or PGEN?

Is CNTA or PGEN more profitable?

Does the media favor CNTA or PGEN?

Do institutionals and insiders hold more shares of CNTA or PGEN?

Do analysts prefer CNTA or PGEN?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Which has preferable valuation & earnings, PGEN or MIRM?

Is PGEN or MIRM more profitable?

Which has more volatility and risk, PGEN or MIRM?

Do institutionals & insiders have more ownership in PGEN or MIRM?

Does the media prefer PGEN or MIRM?

Do analysts prefer PGEN or MIRM?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Which has higher valuation and earnings, RYTM or PGEN?

Do analysts rate RYTM or PGEN?

Is RYTM or PGEN more profitable?

Does the media favor RYTM or PGEN?

Which has more volatility and risk, RYTM or PGEN?

Do institutionals and insiders believe in RYTM or PGEN?

Summary

How does Precigen compare to Cogent Biosciences?

Which has more volatility and risk, COGT or PGEN?

Is COGT or PGEN more profitable?

Does the media favor COGT or PGEN?

Do institutionals & insiders hold more shares of COGT or PGEN?

Which has higher valuation & earnings, COGT or PGEN?

Do analysts prefer COGT or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools